← Back to patent-cliff list
IMBZ1-8-g
Tier C — Watch / tradeIMBZ1-8-g
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PBP3, Beta Lactamase
Indications (approved)：Urinary tract infection, Pyelonephritis
Regional status
US
-
EU
-
China
Phase II
2026-04-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of IMBZ1-8-g?
Approved indications include: Urinary tract infection, Pyelonephritis.
When does the IMBZ1-8-g patent expire?
No public expiry year is available for IMBZ1-8-g yet; this page updates once verified.
How do I get a quote for IMBZ1-8-g intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29